首页> 美国卫生研究院文献>Human Vaccines Immunotherapeutics >Will vaccine hesitancy compromise our efforts to face the next SARS-CoV-2 epidemic wave?
【2h】

Will vaccine hesitancy compromise our efforts to face the next SARS-CoV-2 epidemic wave?

机译:疫苗会犹豫是否妥协我们面对下一个SARS-COV-2流行波的努力?

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

We have checked the vaccination history of 389 elderly patients (62.9% males, mean age of 78.5 + 8.4 years) hospitalized for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia. Information regarding pneumococcal vaccination was available for 354 patients (91.0%): the overall vaccination coverage rate (VCR) was 19.8% (70/354), 11.3% received only 13-valent pneumococcal conjugate vaccine (PCV13), 3.4% were immunized with 23-valent pneumococcal polysaccharide vaccine (PPSV23), 5.1% received both vaccines. VCR among the elderly population in Liguria Region was 26.2% (118,581/453,082), among them 13.7% received PCV13, 12.4% were immunized with at least one dose of PPSV23. Regarding the 2019–2020 influenza season vaccination data were available for 46 patients: 59% of them were immunized. VCR in the elderly population was 51.7% (234,153/453,082).
机译:我们已经检查了389名老年患者的疫苗接种历史(62.9%,平均年龄为78.5 + 8.4岁)为严重急性呼吸综合征冠状病毒2(SARS-COV-2)肺炎。有关肺炎球菌疫苗接种的信息可用于354名患者(91.0%):总疫苗接种覆盖率(VCR)为19.8%(70/354),11.3%只接受13价肺炎球菌共轭疫苗(PCV13),3.4%被免疫23例肺炎球菌多糖疫苗(PPSV23),5.1%接受疫苗。 Liguria地区的老年人群体中的VCR为26.2%(118,581 / 453,082),其中13.7%接受PCV13,用至少一剂PPSV23免疫12.4%。关于2019-2020流感季节疫苗接种数据可用于46名患者:59%的免疫免疫。老年人口的VCR为51.7%(234,153 / 453,082)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号